These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32325781)

  • 1. Flaxseed (
    Kanikowska D; Korybalska K; Mickiewicz A; Rutkowski R; Kuchta A; Sato M; Kreft E; Fijałkowski M; Gruchała M; Jankowski M; Bręborowicz A; Witowski J
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32325781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flaxseed in pediatric hyperlipidemia: a placebo-controlled, blinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with hypercholesterolemia.
    Wong H; Chahal N; Manlhiot C; Niedra E; McCrindle BW
    JAMA Pediatr; 2013 Aug; 167(8):708-13. PubMed ID: 23733031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Flaxseed (
    Kanikowska D; Malińska A; Mickiewicz A; Zawada A; Rutkowski R; Pawlaczyk K; Sato M; Bręborowicz A; Witowski J; Korybalska K
    Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies.
    Bambauer R; Schiel R; Latza R
    Ther Apher; 2000 Jun; 4(3):213-7. PubMed ID: 10910023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis.
    Weylandt KH; Schmöcker C; Ostermann AI; Kutzner L; Willenberg I; Kiesler S; Steinhagen-Thiessen E; Schebb NH; Kassner U
    Nutrients; 2019 Feb; 11(2):. PubMed ID: 30744123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of flaxseed formulation as a potential therapeutic agent in mitigation of dyslipidemia.
    Saxena S; Katare C
    Biomed J; 2014; 37(6):386-90. PubMed ID: 25163498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new genotype of flax (Linum usitatissimum L.) with decreased susceptibility to fat oxidation: consequences to hematological and biochemical profiles of blood indices.
    Króliczewska B; Miśta D; Króliczewski J; Zawadzki W; Kubaszewski R; Wincewicz E; Żuk M; Szopa J
    J Sci Food Agric; 2017 Jan; 97(1):165-171. PubMed ID: 26956460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
    Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of flaxseed consumption on systemic inflammation and serum lipid profile in hemodialysis patients with lipid abnormalities.
    Khalatbari Soltani S; Jamaluddin R; Tabibi H; Mohd Yusof BN; Atabak S; Loh SP; Rahmani L
    Hemodial Int; 2013 Apr; 17(2):275-81. PubMed ID: 22998533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The scientific basis and future of lipoprotein apheresis.
    Thompson GR
    Ther Apher Dial; 2022 Feb; 26(1):32-36. PubMed ID: 34331508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of plasma low density lipoprotein apheresis on the hepatic secretion of biliary lipids in humans.
    Hillebrant CG; Nyberg B; Einarsson K; Eriksson M
    Gut; 1997 Nov; 41(5):700-4. PubMed ID: 9414982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flaxseed Supplementation Reduces Plasma Lipoprotein(a) Levels: A Meta-Analysis.
    Sahebkar A; Katsiki N; Ward N; Reiner Ž
    Altern Ther Health Med; 2021 May; 27(3):50-53. PubMed ID: 31634874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
    Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
    Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.
    Zenti MG; Stefanutti C; Sanga V; Altomari A; Fabris A; Dauriz M; Bonora E
    J Clin Apher; 2018 Aug; 33(4):546-550. PubMed ID: 29638018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A lipidomic analysis approach in patients undergoing lipoprotein apheresis.
    Schmöcker C; Kassner U; Kiesler S; Bismarck M; Rothe M; Steinhagen-Thiessen E; Weylandt KH
    Atherosclerosis; 2016 Jun; 249():30-5. PubMed ID: 27062407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein apheresis in the management of severe hypercholesterolemia and hyperlipoproteinemia(a)-The Portuguese experience.
    Ferreira L; Palma I; Bacelar C; Queirós JA; Madureira A; Oliveira JC; Ramos MH; Cardoso H
    Transfus Apher Sci; 2018 Oct; 57(5):676-680. PubMed ID: 30287070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein (LDL) apheresis reduces atherogenic and oxidative markers in uremic patients with hyperlipidemia.
    Chen TS; Liou SY; Wu HC; Tsai FJ; Tsai CH; Huang CY; Chang YL
    Int Urol Nephrol; 2011 Jun; 43(2):471-4. PubMed ID: 20229247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of brown and golden flaxseed on the lipid profile, glycemia, inflammatory biomarkers, blood pressure and body composition in overweight adolescents.
    Machado AM; de Paula H; Cardoso LD; Costa NM
    Nutrition; 2015 Jan; 31(1):90-6. PubMed ID: 25441591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.